Literature DB >> 17332488

Circulating apoptotic progenitor cells: a novel biomarker in patients with acute coronary syndromes.

Shmuel Schwartzenberg1, Varda Deutsch, Sofia Maysel-Auslender, Sarina Kissil, Gad Keren, Jacob George.   

Abstract

BACKGROUND: Progenitor CD34 cells are capable of differentiating into endothelial cells and play a role in neoangiogenesis. Circulating CD34+ cells and endothelial progenitor cells are increased in acute coronary syndrome (ACS) patients possibly because of peripheral mobilization. We tested the hypothesis that circulating apoptotic progenitors are detectable in healthy subjects and altered in ACS patients. METHODS AND
RESULTS: Peripheral blood mononuclear cells were isolated by Ficoll density gradient from 53 patients with ACS undergoing coronary angiography and 27 healthy subjects. Apoptosis in progenitor CD34+ cells was assessed using the Annexin V-PE/7-AAD detection kit, and fluorescence-activated cell sorter analysis was performed with triple staining for CD34, annexin-V, and 7-AAD. The percentage of apoptotic CD34+ progenitors was determined in the 2 subject groups and correlated with clinical characteristics. The percentage of apoptotic CD34+ progenitor cells was significantly increased in patients with ACS as compared with healthy subjects and was associated with the extent of coronary stenosis by angiography. There was no significant correlation between apoptotic progenitor CD34+ cells and the other parameters that we examined (age, smoking, hypertension, hyperlipidemia, diabetes mellitus, ejection fraction, creatinine levels, or taking any of the various medications, including beta blockers, thiazides, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium blockers, nitrates, or statins).
CONCLUSION: We established for the first time to our knowledge an assay to detect circulating apoptotic progenitor cells using fluorescein isothiocyanate-anti-CD34 MAb, annexin V-PE, and 7-AAD and found that apoptotic CD34+ cells are increased in ACS patients and in patients with more extensive coronary artery disease. This novel assay may shed new light on the factors governing the hemostasis of progenitor CD34+ cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332488     DOI: 10.1161/ATVBAHA.107.139626

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  9 in total

1.  Arterial erectile dysfunction: reliability of new markers of endothelial dysfunction.

Authors:  S La Vignera; R Condorelli; E Vicari; R D'Agata; A E Calogero
Journal:  J Endocrinol Invest       Date:  2011-11       Impact factor: 4.256

2.  miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin.

Authors:  Dibash K Das; Michelle Naidoo; Adeodat Ilboudo; Jong Y Park; Thahmina Ali; Konstantinos Krampis; Brian D Robinson; Joseph R Osborne; Olorunseun O Ogunwobi
Journal:  Exp Cell Res       Date:  2016-09-29       Impact factor: 3.905

3.  CD34+ circulating cells display signs of immune activation in patients with acute coronary syndrome.

Authors:  Lisa Riesinger; Michael Saemisch; Markus Nickmann; Heiko Methe
Journal:  Heart Vessels       Date:  2018-07-12       Impact factor: 2.037

Review 4.  Progenitor cells and vascular disease.

Authors:  M Jevon; A Dorling; P I Hornick
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

5.  Circulating mesenchymal stem cells microparticles in patients with cerebrovascular disease.

Authors:  Suk Jae Kim; Gyeong Joon Moon; Yeon Hee Cho; Ho Young Kang; Na Kyum Hyung; Donghee Kim; Ji Hyun Lee; Ji Yoon Nam; Oh Young Bang
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

6.  Circulating apoptotic progenitor cells in patients with congestive heart failure.

Authors:  Dael Geft; Shmuel Schwartzenberg; Ori Rogowsky; Ariel Finkelstein; Jacob Ablin; Sofia Maysel-Auslender; Dov Wexler; Gad Keren; Jacob George
Journal:  PLoS One       Date:  2008-09-18       Impact factor: 3.240

7.  Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome.

Authors:  Catherine Gebhard; Eric Rhéaume; Colin Berry; Geneviève Brand; Anne-Elen Kernaleguen; Gabriel Théberge-Julien; Mohammad Afaque Alam; Candace Y W Lee; Laurianne Boileau; Malorie Chabot-Blanchet; Marie-Claude Guertin; Marc-André Lavoie; Jean Grégoire; Réda Ibrahim; Philippe L'Allier; Jean-Claude Tardif
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

8.  DRD4 Mitigates Myocardial Ischemia/Reperfusion Injury in Association With PI3K/AKT Mediated Glucose Metabolism.

Authors:  Xue-Song Liu; Jing Zeng; Yu-Xue Yang; Chun-Lei Qi; Ting Xiong; Geng-Ze Wu; Chun-Yu Zeng; Da-Xin Wang
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

9.  Circulating autoantibodies to endothelial progenitor cells: binding characteristics and association with risk factors for atherosclerosis.

Authors:  Jacob George; Marco Matucci-Cerinic; Iris Bar; Sara Shimoni
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.